NCT06183424 TDCS Stimulation After Covid-19 Infection
| NCT ID | NCT06183424 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul Medipol University Hospital |
| Condition | COVID-19 |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2024-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-10-01 with a primary completion date of 2024-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the effects of bilateral stimulation of the dorsolateral prefrontal cortex (DLPFC) with active tDCS (transcranial direct stimulation/transcranial direct stimulation) on neurocognitive (memory and executive) functions in patients with Covid-19 infection and subjective cognitive complaints, as well as resting-state fMRI In the case of dfMRI, it is aimed to examine the default mode network (DMN) and parietal memory network (PMN) inter- and intra-network connectivity alterations and the hippocampal region connectivity alterations and contribute to the relevant literature.
Eligibility Criteria
Inclusion Criteria: * Have received a positive value from the COVID-19 RT-PCR test in the last 60 days and turned negative * Being between the ages of 18-50 * 21 days have passed since the disease onset date Exclusion Criteria: * Having any neurological or psychiatric disease
Contact & Investigator
Burak Yuluğ, Prof. DR. MD
STUDY DIRECTOR
Alanya Alaaddin Keykubat Üniversitesi
Frequently Asked Questions
Who can join the NCT06183424 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06183424 currently recruiting?
Yes, NCT06183424 is actively recruiting participants. Contact the research team at cennet.parlatan@std.medipol.edu.tr for enrollment information.
Where is the NCT06183424 trial being conducted?
This trial is being conducted at Antalya, Turkey (Türkiye).
Who is sponsoring the NCT06183424 clinical trial?
NCT06183424 is sponsored by Istanbul Medipol University Hospital. The principal investigator is Burak Yuluğ, Prof. DR. MD at Alanya Alaaddin Keykubat Üniversitesi. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.